PMID- 33713196 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20211029 IS - 1559-131X (Electronic) IS - 1357-0560 (Linking) VI - 38 IP - 4 DP - 2021 Mar 13 TI - Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan. PG - 37 LID - 10.1007/s12032-021-01480-3 [doi] AB - We conducted a risk-adapted upfront docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here, we reported an interim analysis of the study. The study enrolled 68 patients with newly diagnosed mHSPC between 2016 and 2018. According to the presence of visceral metastasis, an EOD score >/= 3, or prostate-specific antigen (PSA) level at 3 months of >/= 1 ng/mL, patients were divided into low- and high-risk groups. Patients were treated with androgen deprivation therapy (ADT) with or without bicalutamide; those in the high-risk group received upfront treatment involving six cycles of DOC (70 mg/m(2)). Short-term treatment effect, adverse events, and quality of life (QOL) were evaluated. Fifty (73.5%) were classified in the high-risk group, and 46 (67%) received upfront ADT + DOC. In the ADT + DOC group, 43.5% (20/46) patients achieved a PSA level /= 3. During a median follow-up of 18.5 months, 36.4% (8/22) patients in the ADT group and 43.5% (20/46) in the ADT + DOC group had CRPC. Two QOL scores including the physical status and appetite loss at 6 months significantly worsened in the ADT + DOC group but was resolved by 12 months. Upfront DOC achieved high PSA responses without long-term QOL deterioration. However, the short-term outcomes were limited. Longer follow-up is needed to determine the survival advantage. FAU - Muto, Yumina AU - Muto Y AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. FAU - Narita, Shintaro AU - Narita S AUID- ORCID: 0000-0003-2988-1860 AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. naritashintaro@gmail.com. FAU - Hatakeyama, Shingo AU - Hatakeyama S AD - Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. FAU - Maita, Shinya AU - Maita S AD - Department of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan. FAU - Chiba, Shuji AU - Chiba S AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. FAU - Kubo, Kyohei AU - Kubo K AD - Department of Urology, Hiraka General Hospital, Yokote, Japan. FAU - Aoyama, Yuu AU - Aoyama Y AD - Department of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan. FAU - Ito, Ryuichi AU - Ito R AD - Department of Urology, Yuri Kumiai General Hospital, Yurihonjo, Japan. FAU - Takahashi, Yoshiko AU - Takahashi Y AD - Department of Urology, Omagari Kousei Medical Center, Akita, Japan. FAU - Takahashi, Shuhei AU - Takahashi S AD - Department of Urology, Akita Red Cross Hospital, Akita, Japan. FAU - Nakamura, Kumiko AU - Nakamura K AD - Department of Urology, Akita City Hospital, Akita, Japan. FAU - Honma, Naoko AU - Honma N AD - Department of Urology, Akita Kousei Medical Center, Akita, Japan. FAU - Sato, Hiromi AU - Sato H AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. FAU - Koizumi, Atsushi AU - Koizumi A AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. FAU - Igarashi, Ryoma AU - Igarashi R AD - Department of Urology, Yokote Municipal Hospital, Akita, Japan. FAU - Okane, Katsumi AU - Okane K AD - Department of Urology, Akita Kousei Medical Center, Akita, Japan. FAU - Ishida, Toshiya AU - Ishida T AD - Department of Urology, Akita City Hospital, Akita, Japan. FAU - Horikawa, Yohei AU - Horikawa Y AD - Department of Urology, Akita Red Cross Hospital, Akita, Japan. FAU - Kumazawa, Teruaki AU - Kumazawa T AD - Department of Urology, Omagari Kousei Medical Center, Akita, Japan. FAU - Akihama, Susumu AU - Akihama S AD - Department of Urology, Yuri Kumiai General Hospital, Yurihonjo, Japan. FAU - Shimoda, Jiro AU - Shimoda J AD - Department of Urology, Iwate Prefectural Isawa Hospital, Oshu, Japan. FAU - Suzuki, Takehiro AU - Suzuki T AD - Department of Urology, Hiraka General Hospital, Yokote, Japan. FAU - Ohyama, Chikara AU - Ohyama C AD - Department of Urology, Hirosaki University School of Medicine, Hirosaki, Japan. FAU - Habuchi, Tomonori AU - Habuchi T AD - Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210313 PL - United States TA - Med Oncol JT - Medical oncology (Northwood, London, England) JID - 9435512 RN - 0 (Androgen Antagonists) RN - 15H5577CQD (Docetaxel) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Aged MH - Androgen Antagonists/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Docetaxel/*therapeutic use MH - Humans MH - Japan MH - Male MH - Middle Aged MH - Prospective Studies MH - Prostate-Specific Antigen/blood MH - Prostatic Neoplasms/*drug therapy/pathology MH - Quality of Life MH - Treatment Outcome OTO - NOTNLM OT - Chemotherapy OT - Docetaxel OT - Hormone naive OT - Hormone sensitive OT - Metastatic OT - Prostate cancer EDAT- 2021/03/14 06:00 MHDA- 2021/10/30 06:00 CRDT- 2021/03/13 12:08 PHST- 2020/11/13 00:00 [received] PHST- 2021/02/13 00:00 [accepted] PHST- 2021/03/13 12:08 [entrez] PHST- 2021/03/14 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] AID - 10.1007/s12032-021-01480-3 [pii] AID - 10.1007/s12032-021-01480-3 [doi] PST - epublish SO - Med Oncol. 2021 Mar 13;38(4):37. doi: 10.1007/s12032-021-01480-3.